Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides
US-2020361977-A1 · Nov 19, 2020 · US
2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
US11254662B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11254662-B2 |
| Application number | US-202117343350-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 9, 2021 |
| Priority date | Sep 25, 2018 |
| Publication date | Feb 22, 2022 |
| Grant date | Feb 22, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Halogenated analogs of 5-aza-2′-deoxycytidine, such as halogenated analogs of 5-aza-4′-thio-2′-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated analogs to inhibit neoplasia are described. In some examples, the halogenated analogs have a structure according to formula Ia, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
First claim
Opening claim text (preview).
We claim: 1. A compound, wherein the compound is 4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-1,3,5-triazin-2(1H)-one: 2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Isotopically modified compounds, e.g. labelled · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- C07H19/12Primary
Triazine radicals · CPC title
- C07D409/04Primary
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11254662B2 cover?
- Halogenated analogs of 5-aza-2′-deoxycytidine, such as halogenated analogs of 5-aza-4′-thio-2′-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated analogs to inhibit neoplasia are described. In some examples, the halogenated analogs have a structure according to formula Ia, or a stereoisomer, tautomer, or ph…
- Who is the assignee on this patent?
- The Usa As Represented By The Sec Dep Of Health And Human Services, Us Health
- What technology area does this patent fall under?
- Primary CPC classification C07H19/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).